Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Review

Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma

Authors: Liang Zhong, Yutong Liu, Kai Wang, Zhijing He, Zhaojian Gong, Zhili Zhao, Yaocheng Yang, Xiaofei Gao, Fangjie Li, Hanjiang Wu, Sheng Zhang, Lin Chen

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Traditional therapeutics have encountered a bottleneck caused by diagnosis delay and subjective and unreliable assessment. Biomarkers can overcome this bottleneck and guide us toward personalized precision medicine for oral squamous cell carcinoma. To achieve this, it is important to efficiently and accurately screen out specific biomarkers from among the huge number of molecules. Progress in omics-based high-throughput technology has laid a solid foundation for biomarker discovery. With credible and systemic biomarker models, more precise and personalized diagnosis and assessment would be achieved and patients would be more likely to be cured and have a higher quality of life. However, this is not straightforward owing to the complexity of molecules involved in tumorigenesis. In this context, there is a need to focus on tumor heterogeneity and homogeneity, which are discussed in detail. In this review, we aim to provide an understanding of biomarker discovery and application for precision medicine of oral squamous cell carcinoma, and have a strong belief that biomarker will pave the road toward future precision medicine.
Literature
1.
Zini A, Czerninski R, Sgan-Cohen HD. Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J Oral Pathol Med. 2010;39:299–305.CrossRefPubMed
2.
Gomez I, Seoane J, Varela-Centelles P, Diz P, Takkouche B. Is diagnostic delay related to advanced-stage oral cancer? A meta-analysis. Eur J Oral Sci. 2009;117:541–6.CrossRefPubMed
3.
4.
Naruse T, Yanamoto S, Matsushita Y, Sakamoto Y, Morishita K, Ohba S, Shiraishi T, Yamada SI, Asahina I, Umeda M. Cetuximab for the treatment of locally advanced and recurrent/metastatic oral cancer: an investigation of distant metastasis. Mol Clin Oncol. 2016;5:246–52.CrossRefPubMedPubMedCentral
5.
6.
7.
8.
9.
10.
Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–9.CrossRefPubMed
11.
12.
Salahshourifar I, Vincent-Chong VK, Chang HY, Ser HL, Ramanathan A, Kallarakkal TG, Rahman ZA, Ismail SM, Prepageran N, Mustafa WM, et al. Downregulation of CRNN gene and genomic instability at 1q21.3 in oral squamous cell carcinoma. Clin Oral Investig. 2015;19:2273–83.CrossRefPubMed
13.
14.
Chen C, Zhang Y, Loomis MM, Upton MP, Lohavanichbutr P, Houck JR, Doody DR, Mendez E, Futran N, Schwartz SM, Wang P. Genome-wide loss of heterozygosity and DNA copy number aberration in HPV-negative Oral squamous cell carcinoma and their associations with disease-specific survival. PLoS One. 2015;10:e0135074.CrossRefPubMedPubMedCentral
15.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra224.CrossRef
16.
Chiappin S, Antonelli G, Gatti R, De Palo EF. Saliva specimen: a new laboratory tool for diagnostic and basic investigation. Clin Chim Acta. 2007;383:30–40.CrossRefPubMed
17.
Principe S, Hui AB, Bruce J, Sinha A, Liu FF, Kislinger T. Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery. Proteomics. 2013;13:1608–23.CrossRefPubMed
18.
Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015;7:293ra104.CrossRefPubMedPubMedCentral
19.
20.
Horak P, Frohling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open. 2016;1:e000094.CrossRefPubMedPubMedCentral
21.
Al-Hebshi NN, Li S, Nasher AT, El-Setouhy M, Alsanosi R, Blancato J, Loffredo C. Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes. Int J Cancer. 2016;139:363–72.CrossRefPubMedPubMedCentral
22.
India Project Team of the International Cancer Genome C. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun. 2013;4:2873.CrossRef
23.
Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, Heisler LE, Beck TA, Simpson JT, Tonon L, et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat Commun. 2015;6:10001.CrossRefPubMed
24.
Lelieveld SH, Spielmann M, Mundlos S, Veltman JA, Gilissen C. Comparison of exome and genome sequencing Technologies for the Complete Capture of protein-coding regions. Hum Mutat. 2015;36:815–22.CrossRefPubMedPubMedCentral
25.
International Human Genome Sequencing C. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931–45.CrossRef
26.
Bland CS, Wang ET, Vu A, David MP, Castle JC, Johnson JM, Burge CB, Cooper TA. Global regulation of alternative splicing during myogenic differentiation. Nucleic Acids Res. 2010;38:7651–64.CrossRefPubMedPubMedCentral
27.
Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40:1413–5.CrossRefPubMed
28.
29.
Roychowdhury S, Chinnaiyan AM. Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin. 2016;66:75–88.CrossRefPubMed
30.
Pertea M. The human transcriptome: an unfinished story. Genes (Basel). 2012;3:344–60.CrossRef
31.
32.
Zhang Q, Zhang J, Jin H, Sheng S. Whole transcriptome sequencing identifies tumor-specific mutations in human oral squamous cell carcinoma. BMC Med Genet. 2013;6:28.
33.
Sivadas VP, Gulati S, Varghese BT, Balan A, Kannan S. The early manifestation, tumor-specific occurrence and prognostic significance of TGFBR2 aberrant splicing in oral carcinoma. Exp Cell Res. 2014;327:156–62.CrossRefPubMed
34.
35.
Yang Q, Xu B, Sun H, Wang X, Zhang J, Yu X, Ma X. A genome-wide association scan of biological processes involved in oral lichen planus and oral squamous cell carcinoma. Medicine (Baltimore). 2017;96:e7012.CrossRef
36.
Zhang HX, Liu OS, Deng C, He Y, Feng YQ, Ma JA, Hu CH, Tang ZG. Genome-wide gene expression profiling of tongue squamous cell carcinoma by RNA-seq. Clin Oral Investig. 2018;22:209–16.CrossRefPubMed
37.
38.
Chakrabarti S, Multani S, Dabholkar J, Saranath D. Whole genome expression profiling in chewing-tobacco-associated oral cancers: a pilot study. Med Oncol. 2015;32:60.CrossRefPubMed
39.
Chen C, Mendez E, Houck J, Fan W, Lohavanichbutr P, Doody D, Yueh B, Futran ND, Upton M, Farwell DG, et al. Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 2008;17:2152–62.CrossRef
40.
Suhr ML, Dysvik B, Bruland O, Warnakulasuriya S, Amaratunga AN, Jonassen I, Vasstrand EN, Ibrahim SO. Gene expression profile of oral squamous cell carcinomas from Sri Lankan betel quid users. Oncol Rep. 2007;18:1061–75.PubMed
41.
Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3:267–75.CrossRefPubMed
42.
Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A. 2000;97:9390–5.CrossRefPubMedPubMedCentral
43.
44.
Cravatt BF, Simon GM, Yates JR 3rd. The biological impact of mass-spectrometry-based proteomics. Nature. 2007;450:991–1000.CrossRefPubMed
45.
46.
Chi LM, Lee CW, Chang KP, Hao SP, Lee HM, Liang Y, Hsueh C, Yu CJ, Lee IN, Chang YJ, et al. Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Mol Cell Proteomics. 2009;8:1453–74.CrossRefPubMedPubMedCentral
47.
Abe T, Maruyama S, Yamazaki M, Xu B, Babkair H, Sumita Y, Cheng J, Yamamoto T, Saku T. Proteomic and histopathological characterization of the interface between oral squamous cell carcinoma invasion fronts and non-cancerous epithelia. Exp Mol Pathol. 2017;102:327–36.CrossRefPubMed
48.
Gustafsson JO, Oehler MK, Ruszkiewicz A, McColl SR, Hoffmann P. MALDI imaging mass spectrometry (MALDI-IMS)-application of spatial proteomics for ovarian cancer classification and diagnosis. Int J Mol Sci. 2011;12:773–94.CrossRefPubMedPubMedCentral
49.
50.
Yuan Y, Xie X, Jiang Y, Wei Z, Wang P, Chen F, Li X, Sun C, Zhao H, Zeng X, et al. LRP6 is identified as a potential prognostic marker for oral squamous cell carcinoma via MALDI-IMS. Cell Death Dis. 2017;8:e3035.CrossRefPubMedPubMedCentral
51.
Matharoo-Ball B, Miles AK, Creaser CS, Ball G, Rees R. Serum biomarker profiling in cancer studies: a question of standardisation? Vet Comp Oncol. 2008;6:224–47.CrossRefPubMed
52.
Yang Y, Huang J, Rabii B, Rabii R, Hu S. Quantitative proteomic analysis of serum proteins from oral cancer patients: comparison of two analytical methods. Int J Mol Sci. 2014;15:14386–95.CrossRefPubMedPubMedCentral
53.
Arellano-Garcia ME, Li R, Liu X, Xie Y, Yan X, Loo JA, Hu S. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci. 2010;11:3106–21.CrossRefPubMedPubMedCentral
54.
Zhang L, Jiang J, Arellano M, Zhang L, Yan X, Wong DT, Hu S. Quantification of serum proteins of metastatic Oral Cancer patients using LC-MS/MS and iTRAQ labeling. Open Proteomics J. 2008;1:72–8.CrossRefPubMedPubMedCentral
55.
Liu J, Duan Y. Saliva: a potential media for disease diagnostics and monitoring. Oral Oncol. 2012;48:569–77.CrossRefPubMed
56.
Bigler LR, Streckfus CF, Dubinsky WP. Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med. 2009;29:71–85.CrossRefPubMed
57.
Gallo C, Ciavarella D, Santarelli A, Ranieri E, Colella G, Lo Muzio L, Lo RL. Potential salivary proteomic markers of Oral squamous cell carcinoma. Cancer Genomics Proteomics. 2016;13:55–61.PubMed
58.
Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, Wei R, Loo JA, Wong DT. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res. 2008;14:6246–52.CrossRefPubMedPubMedCentral
59.
de Jong EP, Xie H, Onsongo G, Stone MD, Chen XB, Kooren JA, Refsland EW, Griffin RJ, Ondrey FG, Wu B, et al. Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions. PLoS One. 2010;5:e11148.CrossRefPubMedPubMedCentral
60.
Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY, Chen SY, Tsai MH, Huang SH, Lin CW. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010;681:41–8.CrossRefPubMed
61.
Shintani S, Hamakawa H, Ueyama Y, Hatori M, Toyoshima T. Identification of a truncated cystatin SA-I as a saliva biomarker for oral squamous cell carcinoma using the SELDI ProteinChip platform. Int J Oral Maxillofac Surg. 2010;39:68–74.CrossRefPubMed
62.
Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54:716–27.CrossRefPubMedPubMedCentral
63.
Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630–41.CrossRefPubMed
64.
Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal Cancer: emerging biomarkers. Gastroenterology. 2015;149:1204–25.CrossRefPubMed
65.
Li Y, Sawalha AH, Lu Q. Aberrant DNA methylation in skin diseases. J Dermatol Sci. 2009;54:143–9.CrossRefPubMed
66.
Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009;41:1350–3.CrossRefPubMedPubMedCentral
67.
Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007;39:457–66.CrossRefPubMed
68.
69.
Shiga K, Ogawa T, Katagiri K, Yoshida F, Tateda M, Matsuura K, Kobayashi T. Differences between oral cancer and cancers of the pharynx and larynx on a molecular level. Oncol Lett. 2012;3:238–43.CrossRefPubMed
70.
Kerkel K, Spadola A, Yuan E, Kosek J, Jiang L, Hod E, Li K, Murty VV, Schupf N, Vilain E, et al. Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet. 2008;40:904–8.CrossRefPubMed
71.
Lee EJ, Luo J, Wilson JM, Shi H. Analyzing the cancer methylome through targeted bisulfite sequencing. Cancer Lett. 2013;340:171–8.CrossRefPubMed
72.
Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD, Pradhan S, Nelson SF, Pellegrini M, Jacobsen SE. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 2008;452:215–9.CrossRefPubMedPubMedCentral
73.
Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, Esteller M. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011;6:692–702.CrossRefPubMed
74.
Towle R, Truong D, Hogg K, Robinson WP, Poh CF, Garnis C. Global analysis of DNA methylation changes during progression of oral cancer. Oral Oncol. 2013;49:1033–42.CrossRefPubMed
75.
Basu B, Chakraborty J, Chandra A, Katarkar A, Baldevbhai JRK, Dhar Chowdhury D, Ray JG, Chaudhuri K, Chatterjee R. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India. Clin Epigenetics. 2017;9:13.CrossRefPubMedPubMedCentral
76.
Khongsti S, Lamare FA, Shunyu NB, Ghosh S, Maitra A, Ghosh S. Whole genome DNA methylation profiling of oral cancer in ethnic population of Meghalaya, north East India reveals novel genes. Genomics. 2017;110:112–23.CrossRefPubMed
77.
Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-Lopez L, Macia-Colon G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, et al. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res (Phila). 2011;4:1061–72.CrossRef
78.
Cheng SJ, Chang CF, Ko HH, Lee JJ, Chen HM, Wang HJ, Lin HS, Chiang CP. Hypermethylated ZNF582 and PAX1 genes in mouth rinse samples as biomarkers for oral dysplasia and oral cancer detection. Head Neck. 2017;40:355–68.CrossRefPubMed
79.
Cheng SJ, Chang CF, Lee JJ, Chen HM, Wang HJ, Liou YL, Yen C, Chiang CP. Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer. Oral Oncol. 2016;62:34–43.CrossRefPubMed
80.
Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.CrossRef
81.
Luo L, Liu H, Dong Z, Sun L, Peng Y, Liu F. Small interfering RNA targeting ILK inhibits EMT in human peritoneal mesothelial cells through phosphorylation of GSK3beta. Mol Med Rep. 2014;10:137–44.CrossRefPubMed
82.
Klinge CM. miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets. Mol Cell Endocrinol. 2015;418(Pt 3):273–97.CrossRefPubMedPubMedCentral
83.
Manikandan M, Deva Magendhra Rao AK, Arunkumar G, Manickavasagam M, Rajkumar KS, Rajaraman R, Munirajan AK. Oral squamous cell carcinoma: microRNA expression profiling and integrative analyses for elucidation of tumourigenesis mechanism. Mol Cancer. 2016;15:28.CrossRefPubMedPubMedCentral
84.
Lajer CB, Nielsen FC, Friis-Hansen L, Norrild B, Borup R, Garnaes E, Rossing M, Specht L, Therkildsen MH, Nauntofte B, et al. Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer. 2011;104:830–40.CrossRefPubMedPubMedCentral
85.
Xu H, Yang Y, Zhao H, Yang X, Luo Y, Ren Y, Liu W, Li N. Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma. Tumour Biol. 2016;37:447–53.CrossRefPubMed
86.
87.
Arunkumar G, Deva Magendhra Rao AK, Manikandan M, Arun K, Vinothkumar V, Revathidevi S, Rajkumar KS, Rajaraman R, Munirajan AK. Expression profiling of long non-coding RNA identifies linc-RoR as a prognostic biomarker in oral cancer. Tumour Biol. 2017;39(4):1010428317698366.
88.
Arunkumar G, Murugan AK, Prasanna Srinivasa Rao H, Subbiah S, Rajaraman R, Munirajan AK. Long non-coding RNA CCAT1 is overexpressed in oral squamous cell carcinomas and predicts poor prognosis. Biomed Rep. 2017;6:455–62.CrossRefPubMedPubMedCentral
89.
Lo Nigro C, Denaro N, Merlotti A, Merlano M. Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Manag Res. 2017;9:363–71.CrossRefPubMedPubMedCentral
90.
91.
Brocklehurst P, Pemberton MN, Macey R, Cotton C, Walsh T, Lewis M. Comparative accuracy of different members of the dental team in detecting malignant and non-malignant oral lesions. Br Dent J. 2015;218:525–9.CrossRefPubMed
92.
Guneri P, Epstein JB. Late stage diagnosis of oral cancer: components and possible solutions. Oral Oncol. 2014;50:1131–6.CrossRefPubMed
93.
Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND, Zhang L. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357–62.PubMed
94.
Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011;4:218–29.CrossRef
95.
Sumino J, Uzawa N, Okada N, Miyaguchi K, Mogushi K, Takahashi K, Sato H, Michikawa C, Nakata Y, Tanaka H, Amagasa T. Gene expression changes in initiation and progression of oral squamous cell carcinomas revealed by laser microdissection and oligonucleotide microarray analysis. Int J Cancer. 2013;132:540–8.CrossRefPubMed
96.
Liu H, Liu XW, Dong G, Zhou J, Liu Y, Gao Y, Liu XY, Gu L, Sun Z, Deng D. P16 methylation as an early predictor for Cancer development from Oral epithelial dysplasia: a double-blind multicentre prospective study. EBioMedicine. 2015;2:432–7.CrossRefPubMedPubMedCentral
97.
Schussel J, Zhou XC, Zhang Z, Pattani K, Bermudez F, Jean-Charles G, McCaffrey T, Padhya T, Phelan J, Spivakovsky S, et al. EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions. Clin Cancer Res. 2013;19:3268–75.CrossRefPubMedPubMedCentral
98.
Hung KF, Liu CJ, Chiu PC, Lin JS, Chang KW, Shih WY, Kao SY, Tu HF. MicroRNA-31 upregulation predicts increased risk of progression of oral potentially malignant disorder. Oral Oncol. 2016;53:42–7.CrossRefPubMed
99.
Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW, Lin SC. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010;16:360–4.CrossRefPubMed
100.
Jamali Z, Asl Aminabadi N, Attaran R, Pournagiazar F, Ghertasi Oskouei S, Ahmadpour F. MicroRNAs as prognostic molecular signatures in human head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2015;51:321–31.CrossRefPubMed
101.
Maclellan SA, Lawson J, Baik J, Guillaud M, Poh CF, Garnis C. Differential expression of miRNAs in the serum of patients with high-risk oral lesions. Cancer Med. 2012;1:268–74.CrossRefPubMedPubMedCentral
102.
Leusink FK, van Es RJ, de Bree R, Baatenburg de Jong RJ, van Hooff SR, Holstege FC, Slootweg PJ, Brakenhoff RH, Takes RP. Novel diagnostic modalities for assessment of the clinically node-negative neck in oral squamous-cell carcinoma. Lancet Oncol. 2012;13:e554–61.CrossRefPubMed
103.
Yuen AP, Ho CM, Chow TL, Tang LC, Cheung WY, Ng RW, Wei WI, Kong CK, Book KS, Yuen WC, et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head Neck. 2009;31:765–72.CrossRefPubMed
104.
Dik EA, Ipenburg NA, Adriaansens SO, Kessler PA, van Es RJ, Willems SM. Poor correlation of histologic parameters between biopsy and resection specimen in early stage Oral squamous cell carcinoma. Am J Clin Pathol. 2015;144:659–66.CrossRefPubMed
105.
Schilling C, Shaw R, Schache A, McMahon J, Chegini S, Kerawala C, McGurk M. Sentinel lymph node biopsy for oral squamous cell carcinoma. Where are we now? Br J Oral Maxillofac Surg. 2017;55:757–62.CrossRefPubMed
106.
Ogawara K, Miyakawa A, Shiba M, Uzawa K, Watanabe T, Wang XL, Sato T, Kubosawa H, Kondo Y, Tanzawa H. Allelic loss of chromosome 13q14.3 in human oral cancer: correlation with lymph node metastasis. Int J Cancer. 1998;79:312–7.CrossRefPubMed
107.
108.
Dhanda J, Triantafyllou A, Liloglou T, Kalirai H, Lloyd B, Hanlon R, Shaw RJ, Sibson DR, Risk JM. SERPINE1 and SMA expression at the invasive front predict extracapsular spread and survival in oral squamous cell carcinoma. Br J Cancer. 2014;111:2114–21.CrossRefPubMedPubMedCentral
109.
van Hooff SR, Leusink FK, Roepman P, Baatenburg de Jong RJ, Speel EJ, van den Brekel MW, van Velthuysen ML, van Diest PJ, van Es RJ, Merkx MA, et al. Validation of a gene expression signature for assessment of lymph node metastasis in oral squamous cell carcinoma. J Clin Oncol. 2012;30:4104–10.CrossRefPubMed
110.
Mes SW, Te Beest D, Poli T, Rossi S, Scheckenbach K, van Wieringen WN, Brink A, Bertani N, Lanfranco D, Silini EM, et al. Prognostic modeling of oral cancer by gene profiles and clinicopathological co-variables. Oncotarget. 2017;8:59312–23.CrossRefPubMedPubMedCentral
111.
Pathak KA, Juvekar AS, Radhakrishnan DK, Deshpande MS, Pai VR, Chaturvedi P, Pai PS, Chaukar DA, D'Cruz AK, Parikh PM. In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy. Indian J Cancer. 2007;44:142–6.CrossRefPubMed
112.
Kobayashi H, Koike T, Nakatsuka A, Kurita H, Sagara J, Taniguchi S, Kurashina K. Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma. Oral Oncol. 2005;41:38–47.CrossRefPubMed
113.
Su L, Wang Y, Xiao M, Lin Y, Yu L. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:484–91.CrossRefPubMed
114.
Naik PP, Das DN, Panda PK, Mukhopadhyay S, Sinha N, Praharaj PP, Agarwal R, Bhutia SK. Implications of cancer stem cells in developing therapeutic resistance in oral cancer. Oral Oncol. 2016;62:122–35.CrossRefPubMed
115.
Foy JP, Bazire L, Ortiz-Cuaran S, Deneuve S, Kielbassa J, Thomas E, Viari A, Puisieux A, Goudot P, Bertolus C, et al. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. BMC Med. 2017;15:165.CrossRefPubMedPubMedCentral
116.
Chen TC, Wu CT, Wang CP, Hsu WL, Yang TL, Lou PJ, Ko JY, Chang YL. Associations among pretreatment tumor necrosis and the expression of HIF-1alpha and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof. Oral Oncol. 2015;51:1004–10.CrossRefPubMed
117.
Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K, Azuma M. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 2006;42:268–74.CrossRefPubMed
118.
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.CrossRefPubMedPubMedCentral
119.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefPubMedPubMedCentral
120.
Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501–5.PubMed
121.
Chikui T, Yuasa K, Inagaki M, Ohishi M, Shirasuna K, Kanda S. Tumor recurrence criteria for postoperative contrast-enhanced computed tomography after surgical treatment of oral cancer and flap repair. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:369–76.CrossRefPubMed
122.
Kunkel M, Forster GJ, Reichert TE, Jeong JH, Benz P, Bartenstein P, Wagner W, Whiteside TL. Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management. Cancer. 2003;98:2257–65.CrossRefPubMed
123.
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC. Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: how and when? Cancer. 2008;112:94–103.CrossRefPubMed
124.
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38.CrossRefPubMed
125.
Hamana K, Uzawa K, Ogawara K, Shiiba M, Bukawa H, Yokoe H, Tanzawa H. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br J Cancer. 2005;92:2181–4.CrossRefPubMedPubMedCentral
126.
Diwakar N, Sperandio M, Sherriff M, Brown A, Odell EW. Heterogeneity, histological features and DNA ploidy in oral carcinoma by image-based analysis. Oral Oncol. 2005;41:416–22.CrossRefPubMed
127.
Bhawal UK, Tsukinoki K, Sasahira T, Sato F, Mori Y, Muto N, Sugiyama M, Kuniyasu H. Methylation and intratumoural heterogeneity of 14-3-3 sigma in oral cancer. Oncol Rep. 2007;18:817–24.PubMed
128.
129.
Tabatabaeifar S, Thomassen M, Larsen MJ, Larsen SR, Kruse TA, Sorensen JA. The subclonal structure and genomic evolution of oral squamous cell carcinoma revealed by ultra-deep sequencing. Oncotarget. 2017;8:16571–80.CrossRefPubMedPubMedCentral
130.
Wang X, Fan M, Chen X, Wang S, Alsharif MJ, Wang L, Liu L, Deng H. Intratumor genomic heterogeneity correlates with histological grade of advanced oral squamous cell carcinoma. Oral Oncol. 2006;42:740–4.CrossRefPubMed
131.
Adami GR, Tang JL, Markiewicz MR. Improving accuracy of RNA-based diagnosis and prognosis of oral cancer by using noninvasive methods. Oral Oncol. 2017;69:62–7.CrossRefPubMedPubMedCentral
132.
Li X, Di B, Shang Y, Zhou Y, Cheng J, He Z. Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas. Eur J Surg Oncol. 2009;35:1348–53.CrossRefPubMed
133.
Misawa K, Mochizuki D, Endo S, Mima M, Misawa Y, Imai A, Shinmura K, Kanazawa T, Carey TE, Mineta H. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: potential utility as biomarkers for prognosis. Mol Carcinog. 2017;56:1107–16.CrossRefPubMed
134.
Noorlag R, van Kempen PM, Moelans CB, de Jong R, Blok LE, Koole R, Grolman W, van Diest PJ, van Es RJ, Willems SM. Promoter hypermethylation using 24-gene array in early head and neck cancer: better outcome in oral than in oropharyngeal cancer. Epigenetics. 2014;9:1220–7.CrossRefPubMedPubMedCentral
135.
Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12:323–34.CrossRefPubMed
136.
Neuhausen SL. Ethnic differences in cancer risk resulting from genetic variation. Cancer. 1999;86:2575–82.CrossRefPubMed
137.
Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet. 2003;4:293–340.CrossRefPubMed
138.
Saeed AA, Sims AH, Prime SS, Paterson I, Murray PG, Lopes VR. Gene expression profiling reveals biological pathways responsible for phenotypic heterogeneity between UK and Sri Lankan oral squamous cell carcinomas. Oral Oncol. 2015;51:237–46.CrossRefPubMed
139.
Csosz E, Labiscsak P, Kallo G, Markus B, Emri M, Szabo A, Tar I, Tozser J, Kiss C, Marton I. Proteomics investigation of OSCC-specific salivary biomarkers in a Hungarian population highlights the importance of identification of population-tailored biomarkers. PLoS One. 2017;12:e0177282.CrossRefPubMedPubMedCentral
140.
141.
Tabatabaeifar S, Larsen MJ, Larsen SR, Kruse TA, Thomassen M, Sorensen JA. Investigating a case of possible field cancerization in oral squamous cell carcinoma by the use of next-generation sequencing. Oral Oncol. 2017;68:74–80.CrossRefPubMed
142.
Sun Y, Sang Z, Jiang Q, Ding X, Yu Y. Transcriptomic characterization of differential gene expression in oral squamous cell carcinoma: a meta-analysis of publicly available microarray data sets. Tumour Biol. 2016;37:15913–24.CrossRef
143.
Sharma V, Nandan A, Sharma AK, Singh H, Bharadwaj M, Sinha DN, Mehrotra R. Signature of genetic associations in oral cancer. Tumour Biol. 2017;39(10):1010428317725923.
144.
145.
Ikeda T, Seki S, Fujiwara M, Matsuura M, Ozaki-Honda Y, Fujita S, Ikeda H, Umeda M, Asahina I. Low-risk population among patients with tumor-node-metastasis stage III/IV oral squamous cell carcinoma. Oncol Lett. 2017;14:3711–6.CrossRefPubMedPubMedCentral
146.
Turkseven MR, Oygur T. Evaluation of natural killer cell defense in oral squamous cell carcinoma. Oral Oncol. 2010;46:e34–7.CrossRefPubMed
147.
Al-Qahtani D, Anil S, Rajendran R. Tumour infiltrating CD25+ FoxP3+ regulatory T cells (Tregs) relate to tumour grade and stromal inflammation in oral squamous cell carcinoma. J Oral Pathol Med. 2011;40:636–42.CrossRefPubMed
148.
Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr Opin Genet Dev. 2009;19:67–73.CrossRefPubMed
149.
Kartha VK, Stawski L, Han R, Haines P, Gallagher G, Noonan V, Kukuruzinska M, Monti S, Trojanowska M. PDGFRbeta is a novel marker of stromal activation in Oral squamous cell carcinomas. PLoS One. 2016;11:e0154645.CrossRefPubMedPubMedCentral
150.
Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ Jr, Yokota SJ, Bankert RB. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol. 2007;178:5552–62.CrossRefPubMed
151.
Loyher PL, Rochefort J, Baudesson de Chanville C, Hamon P, Lescaille G, Bertolus C, Guillot-Delost M, Krummel MF, Lemoine FM, Combadiere C, Boissonnas A. CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity. Cancer Res. 2016;76:6483–94.CrossRefPubMed
152.
Shirako Y, Taya Y, Sato K, Chiba T, Imai K, Shimazu Y, Aoba T, Soeno Y. Heterogeneous tumor stromal microenvironments of oral squamous cell carcinoma cells in tongue and nodal metastatic lesions in a xenograft mouse model. J Oral Pathol Med. 2015;44:656–68.CrossRefPubMed
153.
Gupta N, Gupta R, Acharya AK, Patthi B, Goud V, Reddy S, Garg A, Singla A. Changing trends in oral cancer - a global scenario. Nepal J Epidemiol. 2016;6:613–9.CrossRefPubMedPubMedCentral
154.
Bessa SS, Hamdy SM, El-Sheikh RG. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. Eur J Intern Med. 2010;21:530–5.CrossRefPubMed
155.
Yu-Duan T, Chao-Ping W, Chih-Yu C, Li-Wen L, Tsun-Mei L, Chia-Chang H, Fu-Mei C, Hsien-Chang L, Hsia-Fen H, Yau-Jiunn L, Jer-Yiing H. Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients. Med Oral Patol Oral Cir Bucal. 2013;18:e180–6.CrossRefPubMed
156.
Acharya S, Kale J, Hallikeri K, Anehosur V, Arnold D. Clinical significance of preoperative serum C-reactive protein in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2018;47:16–23.CrossRefPubMed
157.
Nalini M, Raghavulu BV, Annapurna A, Avinash P, Chandi V, Swathi N, Wasim. Correlation of various serum biomarkers with the severity of diabetic retinopathy. Diabetes Metab Syndr. 2017;11(Suppl 1):451–4.CrossRef
158.
Metgud R, Patel S. Serum and salivary levels of albumin as diagnostic tools for oral pre-malignancy and oral malignancy. Biotech Histochem. 2014;89:8–13.CrossRefPubMed
159.
Srinivasan M, Blackburn C, Mohamed M, Sivagami AV, Blum J. Literature-based discovery of salivary biomarkers for type 2 diabetes mellitus. Biomark Insights. 2015;10:39–45.CrossRefPubMedPubMedCentral
160.
Govekar RB, D'Cruz AK, Alok Pathak K, Agarwal J, Dinshaw KA, Chinoy RF, Gadewal N, Kannan S, Sirdeshmukh R, Sundaram CS, et al. Proteomic profiling of cancer of the gingivo-buccal complex: identification of new differentially expressed markers. Proteomics Clin Appl. 2009;3:1451–62.PubMed
161.
Tasoulas J, Patsouris E, Giaginis C, Theocharis S. Salivaomics for oral diseases biomarkers detection. Expert Rev Mol Diagn. 2016;16:285–95.CrossRefPubMed
162.
Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007;99:147–57.CrossRefPubMed
163.
Moons KG, Altman DG, Reitsma JB, Collins GS. Transparent reporting of a multivariate prediction model for individual prognosis or development I. new guideline for the reporting of studies developing, validating, or updating a multivariable clinical prediction model: the TRIPOD statement. Adv Anat Pathol. 2015;22:303–5.CrossRefPubMed
164.
Rabbani B, Nakaoka H, Akhondzadeh S, Tekin M, Mahdieh N. Next generation sequencing: implications in personalized medicine and pharmacogenomics. Mol BioSyst. 2016;12:1818–30.CrossRefPubMed
Metadata
Title
Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma
Authors
Liang Zhong
Yutong Liu
Kai Wang
Zhijing He
Zhaojian Gong
Zhili Zhao
Yaocheng Yang
Xiaofei Gao
Fangjie Li
Hanjiang Wu
Sheng Zhang
Lin Chen
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4806-7

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Hereditary breast and ovarian cancer in Andalusian families: a genetic population study

Research article

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

Research article

Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice

Study protocol

Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol

Study protocol

Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT

Research article

Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits